Abstract 1755P
Background
Obesity is a strong risk factor for cancer, with more than 40,000 diagnosed cancers every year attributed to obesity. The role of nutrition in obesity-related cancers (ORC) needs to be better understood to develop tailored prevention strategies. The quality, rather than the quantity, of carbohydrate intake, seems to play a significant role. We investigated the relationship between dietary carbohydrate quality and risk of developing ORC in the "Seguimiento Universidad de Navarra” (SUN) Mediterranean cohort.
Methods
A total of 18,446 Spanish university graduates [mean age 38 years (SD 12), 61% women, mean BMI 23.5 kg/m2 (SD 3.5 kg/m2)], with no personal history of cancer, were followed-up for a median of 13.7 years. Baseline carbohydrate quality index (CQI) was assessed using 4 previously defined criteria: high dietary fibre intake, low glycemic index, high whole-grain: total-grain ratio and high solid carbohydrate: total carbohydrate ratio. Subjects were classified into tertiles according to their CQI score. Obesity-related incident cases were confirmed by an oncologist using medical records and by querying the National Death Index blindly to dietary exposures.
Results
During follow-up, 269 incident cases of obesity-related cancer were confirmed. A higher quality of carbohydrate intake, as measured by the baseline CQI, was associated with a lower risk of ORC with multivariable-adjusted hazard ratio (HR) for the upper (T3) versus the lowest tertile (T1) of 0.68 (95% confidence interval: 0.48, 0.97). Particularly, a higher dietary fibre intake was inversely associated with ORC, HR T3 vs. T1 = 0.58 (0.38, 0.89).
Conclusions
In this Mediterranean cohort, we observed a significant inverse association between a better global quality of carbohydrate intake and the risk of obesity-related cancers. This finding suggests that strategies for cancer prevention should emphasize the quality of carbohydrate intake, and particularly the dietary fibre intake.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Navarra.
Funding
Spanish Government-Instituto de Salud Carlos III, and the European Regional Development Fund (FEDER) (RD 06/0045, CIBER-OBN, Grants PI10/02658, PI10/02293, PI13/00615, PI14/01668, PI14/01798, PI14/01764, PI17/01795, PI20/00564 and G03/140), the Navarra Regional Government (27/2011, 45/2011, 122/2014), and the University of Navarra.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23